Vertical Venture Partners

Investor type Micro VC
Founders David Schwab


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 44
Average round size
The average size of a deal this fund participated in
Portfolio companies 26
Rounds per year 6.29
Lead investments 6
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 4
Key employees 4

Areas of investment

  • Software
  • Health Care
  • Biotechnology
  • Information Technology
  • SaaS

In 2014 was created Vertical Venture Partners, which is appeared as VC. The fund was located in North America if to be more exact in United States. The main department of described VC is located in the Menlo Park.

Among the most popular portfolio startups of the fund, we may highlight POWWOW, Redeam, Portfolium. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Enterprise Software, Health Care.

Comparing to the other companies, this Vertical Venture Partners performs on 21 percentage points less the average number of lead investments. The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies. The fund is generally included in less than 2 deals every year. The top activity for fund was in 2017. Deals in the range of 5 - 10 millions dollars are the general things for fund. The higher amount of exits for fund were in 2019. The typical startup value when the investment from Vertical Venture Partners is 10-50 millions dollars.

The current fund was established by David Schwab. We also calculated 4 valuable employees in our database.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Vertical Venture Partners, startups are often financed by Accel, Taner Halicioglu, Silicon Valley Growth Syndicate. The meaningful sponsors for the fund in investment in the same round are Grayhawk Capital, Cobre Capital, Seven Peaks Ventures. In the next rounds fund is usually obtained by Seven Peaks Ventures, Grayhawk Capital, Cobre Capital.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Vertical Venture Partners:
Typical Co-investors
Vertical Venture Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Vertical Venture Partners:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Allied Irish Banks Dublin, Ireland, Irishtown
Antares Italy, Lombardy, Milan
Chinese Media China, Guangdong, Jiangxi
CX Venture Group -
Cycle Venture Partners -
EV -
Excell Technology Ventures -
Good News Ventures Canada, Ontario, Toronto
Impres Health -
Medalist Capital Charlotte, North Carolina, United States
Newfort Capital -
NewGaoQiao E-Business China, Fujian, Hunan
Nokia Venture Partners California, Kentucky, United States
Owl Ventures California, San Francisco, United States
Ricoh Company Japan, Tokyo
Servier Canada -
Stratim Capital California, San Francisco, United States
The Libra Foundation California, San Francisco, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Artificial Intelligence
Business Intelligence
Data Visualization
Enterprise Software
Life Science
$8M14 Dec 2021 New Jersey, United States

Delix Therapeutics

$70M27 Sep 2021 Boston, Massachusetts, United States

NanoCellect Biomedical

Health Care
Health Diagnostics
Medical Device
$20M13 Aug 2021 San Diego, California, United States

Retina AI

Artificial Intelligence
Big Data
$8M29 Jun 2021 Santa Monica, California, United States

Amira Learning

Artificial Intelligence
Machine Learning
$11M14 Apr 2021 Las Vegas, Nevada, United States

Health Care
$15M05 Apr 2021 New Haven, Connecticut, United States

NanoCellect Biomedical

Health Care
Health Diagnostics
Medical Device
$15M01 Feb 2021 San Diego, California, United States

Concert Health

Health Care
Information Technology
$14M28 Jan 2021 San Diego, California, United States


$5M23 Nov 2020 Madrid, Madrid, Spain
Retina Raises $8 Million Series A to Transform E-Commerce Customer Acquisition

– Retina, the leading predictive customer lifetime value (pCLV) intelligence company, announced it raised an $8m Series A to transform how high-growth brands acquire, retain and expand their most valuable customers.
– The funding will be used to drive the company’s growth, continue its hiring spree, and expand the capabilities of its digital platform with existing integrations and partners, including Facebook, Google, Shopify, Segment, and Experian.
– Retina is the glue that enables brands to make better customer acquisition and service decisions through its AI, machine learning, and data analytics.
– Its platform is privacy-centric and gives marketers proven insights — without relying on cookies or IDFA (Identifier for Advertisers) — that drive improved customer targeting and brand loyalty.
Alpha Intelligence Capital and Vertical Venture Partners led the round.

Edifice Health Raises $12M in Funding

– Edifice Health is a San Mateo, CA-based immunological health and personalized nutrition company.
– Company raised $12m in Series A funding led by Leaps by Bayer with participation from Paladin Capital Group, Vertical Venture Partners, Ahren Innovation Capital, Ataraxia Capital Partners, Shanda Grab Ventures, Alafi Capital, and Taisho Pharmaceutical.
– The funds will be used to grow its foundation of immunological science and add additional talent.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Vertical Venture Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: